DBP partners with Webpharma SPT in Norway

Report this content

Double Bond Pharmaceuticals subsidiary Drugsson has signed a distribution agreement with Webpharma SPT in Norway. According to the agreement, Webpharma will be Drugsson's wholesaler and distribution partner in the Norwegian market.

"With this agreement, we now have a partner who has a great experience in the Norwegian market," comments Igor Lokot, CEO of Double Bond Pharma and Drugsson AB. – This collaboration will substantially propel Drugssons expansion to Norway”.

Webpharma SPT are also active on the health care professional market and supplies pharmaceuticals to clinics and hospitals throughout Norway (doctors, dentists and veterinarians). They have direct agreements with several large and small pharmaceutical companies.

More about Webpharma SPT: https://www.webpharma.no/

More about Drugsson AB: www.drugsson.com

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11 of March 2019.

For more info, contact
Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com 

Blog: http://blog.doublebp.com

Follow us on LinkedIn, Facebook and Twitter!

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. DBP has during the past year also started two subsidiaries, Drugsson AB for the distribution of fully developed human pharmaceutical and medical device products and dietary supplements in Scandinavia, and FarmPharma AB for the development of innovative veterinary products.



Documents & Links